We strive to be a global biopharma leader whose mission is
to develop innovative, life-changing medicine
Pipeline
Ivaltinostat
-
Indication
Pancreatic ductal adenocarcinoma (PDAC), myelodysplastic syndrome (MDS), acute myelogenous leukemia (AML), hepatocellular carcinoma (HCC)
-
Development stage
- Completed Phase 2 clinical studies for PDAC patients
- Phase 2 clinical study in progress for patients with MDS
- AML and HCC clinical studies in development
Ivaltinostat
-
01
Best-in-class (i.e., best inhibitor effect amongst similar HDAC inhibitors)
-
02
Improved efficacy compared to existing treatments based on Phase 2 clinical study for PDAC
(Disease control rate 93.8%, overall survival rate 10.8 months) -
03
Significantly improved safety compared to existing treatments in PDAC based on Phase 2 clinical study results
(3등급 이상의 비혈액학적 부작용이 현저히 적게 나타남) -
04
FDA orphan drug designation:
HCC, AML, PDAC
MFDS developmental orphan drug
designation:
PDAC, MDS
Deacetylation of histone protein
Regulates the expression of genes by managing the process of DNA condensation around histone proteins
Abnormal HDAC expression
Induction of persistent histone protein de-acetylation (promotes DNA condensation)
Decreased expression of cancer suppressor genes
Infinite growth of mutant cells
Cancer development
-
Anticancer effect, epigenetic homeostasis recovery
- Promoting cancer suppressor gene expression by inhibiting overexpressed HDACs
- Inhibiting tumor cell proliferation (increases P21 expression, induces P53 acetylation) or induces tumor cell suicide
- Restoring anticancer drug efficacy (Gemcitabine, 5-Fu) - i.e., chemoresistance is removed and cancer cells are once again sensitive to chemotherapy
-
Immunomodulation effect that promotes the anti-tumor immune response of the body
- Increasing cytotoxic T cells, promoting NK cell activity
- Inhibiting proliferation of immunosuppressed cells (M2 macrophages, MDSC (Myeloid-Derived Suppressor Cells), Regulatory T cells)
- Inducting synergistic effect against immune checkpoint inhibitor (anti-PD-1 antibody)
-
1.
Kim, Y.D. et al. HDAC Inhibitor, CG-745, enhances the anti-cancer effect of anti-PD-1 immune checkpoint inhibitor by modulation of the immune microenvironment. J. Cancer. 11, 4059-4072 (2020).
-
2.
Kim, Y.S. et al. The anti-fibrotic effects of CG-745, an HDAC inhibitor, in bleomycin and PHMG-induced mouse models. Molecules 24, 2792 (2019).
-
3.
Yoon, G.E. et al. Histone deacetylase inhibitor CG200745 ameliorates high-fat diet-induced hypertension via inhibition of angiotensin II production. Naunyn-Schmiedebergs Arch. Pharmacol. 393, 491-500 (2020).
-
4.
Oh, E.T. et al. Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.
Invest. New Drugs 30, 435-442 (2012). -
5.
Jung, D.E. et al. CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the hippo pathway. Sci. Rep. 7, 10921 (2017).
-
6.
Lee, H.S. et al. A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance. Sci. Rep. 7, 41615 (2017).